

# READY ON DAY 1

August 2024

**3,000,000** lives lost worldwide before vaccines were available

**15** percent increase in US mortality

**23,000,000** US jobs lost

**14,000,000,000,000** dollars in US economic damage

**3.5** percent decrease in global GDP

## Imagine if we had been ready

**7,054,000** deaths worldwide

**20** years of US educational progress erased

**1,190,000** US deaths—70% more than *all combat deaths since 1775*

**65,000,000** long COVID cases worldwide

**30** percent of global population remains unvaccinated

**Bold action now,  
because the next  
pandemic is  
inevitable**



- Deadly new viruses are emerging more frequently.
- Vaccines end pandemics, but are reactive not proactive.
- Antiviral drugs — pills swallowed with a drink of water — offer first-line defense to reduce disease, hospitalization and death.



**Deployed on Day 1,  
antivirals can stop  
another catastrophe.**




## Planning for the next pandemic

---

- Viruses cluster into families.
- Viruses within each family share common features that can be targeted by antiviral drugs.

No one knows which specific viruses come next, but we do know the *families* from which they will likely emerge.



**Broad-spectrum small molecule antivirals exploit vulnerabilities shared within a virus family.**

***broad-spectrum:***

effective against multiple viruses in a given family

***small molecule drugs:***

organic compounds with low molecular weight (think aspirin, not biologics)

Antivirals that work against an entire virus family

- Treat existing viruses
- Protect against future threats
- No need to wait for specific genetic sequence

Pills that can be shipped immediately, without refrigeration, to the point of outbreak and taken with a drink of water

- Reduce disease, hospitalization and death
- Slow viral spread

**GOAL: 2 broad-spectrum drugs per high-risk family**



## The world's experts are in agreement ...

“Small-molecule antivirals are **the most effective treatment** for a new virus ... . Therapeutics should be a cornerstone of an effective rapid response to a new virus.”

— *100 Days Mission Therapeutics Roadmap*, published Jan. 2024 by the G7's International Pandemic Preparedness Secretariat (IPPS), the world's leading global pandemic preparedness effort

“Prioritization of diagnostics, therapeutics, and vaccines that offer **broad coverage** with little necessary updating would be ideal to deliver rapid benefits **against entire pathogen families** ... . Therapeutics are crucial due to multiple uncertainties about the next pandemic; the world should invest accordingly.”

— *The Lancet*, “The 100 Days Mission: how a new medical-countermeasures network can deliver equity and innovation,” Sep. 2023

During the 2022 omicron wave, even if only 1 out of 5 symptomatic COVID-19 patients had received the **antiviral therapeutic Paxlovid**, it would have **prevented up to 850,000 hospitalizations and 33,000 deaths** and saved up to \$170 billion.

— *Emerging Infectious Diseases*, “Public Health Impact of Paxlovid,” U.S. Centers for Disease Control and Prevention, Feb. 2024



**“Why isn’t anyone else doing this?”**

**Discovery gap**

Academics focus on drug discovery, not drug development.

**Pharma model**

Businesses develop drugs to target specific indications for existing markets.

**Disease X problem**

There is no business model to fight diseases that don’t yet exist.

**CHALLENGE: Incentivize antiviral development to prepare for Disease X**

## READDI is the solution

A mission-driven biotechnology company acting in the public interest, READDI accelerates broad-spectrum small molecule antiviral discovery and development.

Committed to equitable global access

Addressing market failure to disrupt the panic-neglect cycle of pandemic response





# Leadership

Founded in 2020 by world-renowned virologists



**Ralph S. Baric**  
Co-founder and  
Scientific Adviser



**Mark Heise**  
Co-founder and  
Scientific Adviser



**Nathaniel Moorman**  
Co-founder and  
Scientific Adviser



**James Rosen**  
CEO and Director



**Fletcher Fairey**  
Executive VP,  
Business



**Logan Ward**  
Director of  
Communications

# Select Board Members



**John Bamforth**  
30 years at Eli Lilly



**Richard Burr**  
Former U.S.  
Senator



**Laurent Fraise**  
R&D Dir, Drugs for  
Neglected Diseases Init



**Lydia Ogden**  
Global Public Health  
R&D Policy and  
External Engagement  
Leader, J&J



**Barbara Stephenson**  
UNC Chief Global  
Officer and former  
U.S. Ambassador



**Brad Wilken**  
Bill & Melinda  
Gates Foundation




# Preparing for the next threat




## High-risk virus families


- Encompass all viruses that cause WHO priority diseases
- Likely origin of future Disease X
- No antivirals or vaccines exist to stop Disease X



Arenavirus




Bunyavirus




Coronavirus




Filovirus




Flavivirus



Orthomyxovirus




Paramyxovirus



Togavirus



# READDI Prospective Pipeline





**World-class drug development and innovative financing to prepare humanity for Disease X.**




# READDI leads the world in antiviral therapeutics R&D

- Core implementation partner in the 100 Days Mission, the global pandemic preparedness effort launched by the G7
- Lead contributor to *100 Days Mission Therapeutics Roadmap*
- Co-leading new Therapeutics Coalition alongside the WHO, UNITAID, DNDi and others

“The highest priority is to gather resources to support READDI’s work. You can make all the plans you want on the clinical implementation and distribution, but if you don’t have the drugs, it doesn’t matter. Drugs are the gating item.”

— Jeremy Farrar, WHO Chief Scientist, addressing Therapeutics Coalition leadership



# Funders



THE UNIVERSITY  
of NORTH CAROLINA  
at CHAPEL HILL



**BATTELLE**



**RTI**  
INTERNATIONAL



Help us prepare  
for the next  
pandemic.



**READI**

Rapidly Emerging Antiviral Drug Development Initiative